Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Br J Radiol Retrieve available abstracts of 38 articles: HTML format

Single Articles

September 2025
1. LANDRY C, Klusa D, Cochonneau D, Supiot S, et al
   Circulating tumor cells for the prediction of the response to radiation therapy in prostate cancer.
   Br J Radiol. 2025 Sep 13:tqaf224. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2025
2. HE CL, Yang T, Zhang MN, Yao J, et al
   A Novel Approach to Differentiate Prostate Cancer from Prostatitis in the Peripheral Zone.
   Br J Radiol. 2025 Aug 20:tqaf186. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2025
3. WYATT JJ, Hedley S, Richmond N, West S, et al
   Dose differences between patients treated with MR-only, CT-only or MR-CT fusion radiotherapy for prostate cancer.
   Br J Radiol. 2025 Jul 16:tqaf159. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2025
4. POON DMC, Yuan J, Cao M, Yang Y, et al
   Optimizing Lymph Node Metastasis Imaging in MR-Guided Radiotherapy for Oligometastatic Prostate Cancer.
   Br J Radiol. 2025 Jun 23:tqaf142. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. MARGOLESE N, Dahan J, Olivie DAR, Billiard JS, et al
   Prognostic factors of biochemical recurrence and impact of pre-treatment MRI for prostate cancer radiotherapy.
   Br J Radiol. 2025 Jun 2:tqaf122. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. AZRIA D, Haviland JS, Brengues M, Griffin C, et al
   Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers.
   Br J Radiol. 2025;98:929-937.
   PubMed     Abstract available
   
   
   
7. AZRIA D, Haviland JS, Brengues M, Griffin C, et al
   Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers.
   Br J Radiol. 2025;98:929-937.
   PubMed     Abstract available
   
   
   January 2025
8. MIRSHAHVALAD SA, Basso Dias A, Ortega C, Abreu Gomez JA, et al
   18F-DCFPyL PET/MRI Radiomics for Intraprostatic Prostate Cancer Detection and Metastases Prediction Using Whole-Gland Segmentation.
   Br J Radiol. 2025 Jan 23:tqaf014. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2024
9. GUTIERREZ-VALENCIA E, Navarro-Domenech I, Zhou K, Barcelona M, et al
   Partial or Focal Brachytherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
   Br J Radiol. 2024 Dec 19:tqae254. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. 
    Correction: Proton therapy for prostate cancer: current state and future perspectives.
    Br J Radiol. 2024 Dec 11:tqae245. doi: 10.1093.
    PubMed    
    
    
    November 2024
11. LEE KL, Kessler DA, Caglic I, Kuo YH, et al
    Assessing the Performance of ChatGPT and Bard/Gemini Against Radiologists for PI-RADS Classification Based on Prostate Multiparametric MRI Text Reports.
    Br J Radiol. 2024 Nov 13:tqae236. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. SUZUKI C, Matsubara K, Ujihara Y, Isogai K, et al
    Dual Energy Metal Artifact Reduction for Iodine-125 Seed Identification in Postimplant CT after Prostate Brachytherapy.
    Br J Radiol. 2024 Nov 4:tqae225. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
13. ZENG HJ, Yang L, Yao J
    Multiparameter magnetic resonance imaging features of prostatic malakoplakia.
    Br J Radiol. 2024 Oct 8:tqae205. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
14. PARK SH, Choi MH, Lee YJ, Jung SE, et al
    Rationale for Adopting a Combination of Monoparametric MRI with the Prostate-Specific Antigen in Detecting Clinically Significant Prostate Cancer: Comparison with Standard Biparametric and Multiparametric MRI.
    Br J Radiol. 2024 Aug 30:tqae134. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
15. STARKE A, Poxon J, Patel K, Wells P, et al
    Clinical evaluation of the efficacy of limbus artificial intelligence software to augment contouring for prostate and nodes radiotherapy.
    Br J Radiol. 2024;97:1125-1131.
    PubMed     Abstract available
    
    
    
16. XIAO Y, Zeng Y, Han L, Lin G, et al
    A novel simplified transperineal prostate biopsy guided by perineal ultrasound.
    Br J Radiol. 2024 May 23:tqae097. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. NAIK M, Khan SR, Lewington V, Challapalli A, et al
    Imaging and therapy in prostate cancer using PSMA radioligands.
    Br J Radiol. 2024 May 11:tqae092. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. REINHARDT C, Briody H, MacMahon PJ
    AI-Accelerated prostate MRI: a systematic review.
    Br J Radiol. 2024 May 8:tqae093. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
19. 
    Correction to: High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
    Br J Radiol. 2024 Apr 30:tqae083. doi: 10.1093.
    PubMed    
    
    
    
20. IN DE BRAEKT T, van Rooij SBT, Daniels-Gooszen AW, Scheepens WA, et al
    Accuracy of Magnetic Resonance Imaging-Ultrasound Fusion-Guided and Systematic Biopsy of the Prostate.
    Br J Radiol. 2024 Apr 16:tqae080. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
21. MARTINI F, Pigati M, Mattiauda M, Ponzano M, et al
    Extra-prostatic extension (EPE) grading system: Correlation with MRI features and integration of capsular enhancement sign (CES) for "enhanced" detection of T3a lesions.
    Br J Radiol. 2024 Mar 27:tqae065. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. TAKANO S, Tomita N, Takaoka T, Niwa M, et al
    Late genitourinary toxicity in salvage radiotherapy for prostate cancer after radical prostatectomy: impact of daily fraction doses.
    Br J Radiol. 2024 Mar 11:tqae055. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
23. MCDAID L, Clough A, Benson KR, Nelder C, et al
    Geometric distortion caused by metallic femoral head prosthesis in prostate cancer imaging on an MR linac: in-vivo measurements of spatial deformation.
    Br J Radiol. 2024 Feb 24:tqae044. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. PAN K, Yao F, Hong W, Xiao J, et al
    Multimodal radiomics based on 18F-Prostate-specific membrane antigen-1007 PET/CT and multiparametric MRI for prostate cancer extracapsular extension prediction.
    Br J Radiol. 2024;97:408-414.
    PubMed     Abstract available
    
    
    
25. CHENG T, Li H
    Prediction of Gleason score in prostate cancer patients based on radiomic features of transrectal ultrasound images.
    Br J Radiol. 2024;97:415-421.
    PubMed     Abstract available
    
    
    January 2024
26. GIACOMETTI V, Grey AC, McCann AJ, Prise KM, et al
    An objective measure of response on whole-body MRI in metastatic hormone sensitive prostate cancer treated with androgen deprivation therapy, external beam radiotherapy, and radium-223.
    Br J Radiol. 2024 Jan 24:tqae005. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. ALI I, Rezk M, Hamouda D, Talaat O, et al
    Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate to high risk prostate cancer.
    Br J Radiol. 2024 Jan 23:tqae021. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. WINTER JD, Reddy V, Li W, Craig T, et al
    Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review.
    Br J Radiol. 2024;97:31-40.
    PubMed     Abstract available
    
    
    
29. AGGARWAL P, Krishna Kumar RG, Das CJ, Kubihal V, et al
    Role of non-contrast CT component of prostate-specific membrane antigen PET/CT scan in the detection of peripheral zone prostate cancer.
    Br J Radiol. 2024;97:195-200.
    PubMed     Abstract available
    
    
    
30. MURAKAMI Y, Kawahara D, Soyano T, Kozuka T, et al
    Dosiomics for intensity-modulated radiotherapy in patients with prostate cancer: survival analysis stratified by baseline prostate-specific antigen and Gleason grade group in a 2-institutional retrospective study.
    Br J Radiol. 2024;97:142-149.
    PubMed     Abstract available
    
    
    
31. RAJENDRAN I, Lee KL, Thavaraja L, Barrett T, et al
    Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
    Br J Radiol. 2024;97:113-119.
    PubMed     Abstract available
    
    
    
32. MUKHERJEE S, Papadopoulos D, Chari N, Ellis D, et al
    High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model.
    Br J Radiol. 2024 Jan 4:tqad066. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
33. KENDRICK J, Francis R, Hassan GM, Rowshanfarzad P, et al
    Prospective inter- and intra-tracer repeatability analysis of radiomics features in [(68)Ga]Ga-PSMA-11 and [(18)F]F-PSMA-1007 PET scans in metastatic prostate cancer.
    Br J Radiol. 2023 Sep 26:20221178. doi: 10.1259/bjr.20221178.
    PubMed     Abstract available
    
    
    
34. CASTAGNOLI F, Doners R, Tunariu N, Messiou C, et al
    Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement.
    Br J Radiol. 2023 Sep 26:20230240. doi: 10.1259/bjr.20230240.
    PubMed     Abstract available
    
    
    
35. SOLIMAN M, Elfatairy K, Ellessy RMI, Velichko YS, et al
    The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate Resistant Prostate Cancer Patients (nmCRPCp): Diagnostic performance and Impact on Management.
    Br J Radiol. 2023 Sep 26:20230414. doi: 10.1259/bjr.20230414.
    PubMed     Abstract available
    
    
    
36. GREWAL H, Kedar R, Dhillon G, Sidhu G, et al
    SpaceOAR hydrogel complications in prostate cancer: Pictorial review.
    Br J Radiol. 2023 Sep 26:20230717. doi: 10.1259/bjr.20230717.
    PubMed     Abstract available
    
    
    
37. DONNERS R, Candito A, Blackledge M, Rata M, et al
    Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases.
    Br J Radiol. 2023 Sep 3:20230378. doi: 10.1259/bjr.20230378.
    PubMed     Abstract available
    
    
    
38. YATES AH, Power JW, Dempsey PJ, Agnew A, et al
    SpaceOAR hydrogel distribution and early complications in patients undergoing radiation therapy for prostate cancer.
    Br J Radiol. 2023 Sep 3:20220947. doi: 10.1259/bjr.20220947.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.